Scientists identify cancer biomarkers in breast milk
A simple blood test for women of all ages and risk levels could one day be possible thanks to a new set of protein biomarkers that researchers identified using breast milk.
“Although mammograms are a useful tool for catching breast cancer early, they aren’t typically recommended for low-risk women under 40,” said Danielle Whitham, a doctoral candidate at Clarkson University in New York. “Because the biomarkers we found in breast milk are also detectable in blood serum, screening could potentially be done in women of any age using blood or breast milk.”
The newly identified biomarkers are for a specific type of cancer called invasive ductal carcinoma (IDC), one of the most common types of breast cancers. However, the researchers say that their approach could be used to identify biomarkers for other types of breast cancer.
“If our future studies are successful, it could change how women are monitored for breast cancer and aid in earlier diagnosis,” said Whitham. “This could even lead to a higher survival rate in women.”
Whitham will present the research at the American Society for Biochemistry and Molecular Biology annual meeting during the Experimental Biology (EB) 2022 meeting, to be held April 2–5 in Philadelphia.
“We used breast milk because it contains proteins, epithelial cells and immune cells, all of which provide a great deal of information about what is happening in a woman’s body during a crucial time in breast development,” said Whitham.
For the study, breast milk samples were obtained from three women diagnosed with breast cancer and three women without cancer. Using liquid chromatography with tandem mass spectrometry, the researchers compared the relative levels of certain proteins between the two groups to identify differences in the women with cancer. The analysis revealed 23 proteins that were dysregulated. All the proteins that showed differences were previously shown to play a role in cancer or tumor development.
Now that the researchers have identified a biomarker set, they plan to confirm it with a larger group of women. Then, they will test the protein biomarkers’ applicability in blood serum. If those tests are successful, a blood test could be developed to be used on women of any age to monitor protein changes for detection of breast cancer.
Research collaborators on this team include Costel Darie and Sumona Mondal of Clarkson University, Kathleen Arcaro and Brian Pentecost of the University of Massachusetts, Amherst and David Fenyo of New York University School of Medicine.
Women interested in helping with this research by donating breast milk samples can visit http://breastmilkresearch.org.
Danielle Whitham will present this research from 12:30–1:45 p.m. Monday, April 4, in Exhibit/Poster Hall A-B, Pennsylvania Convention Center (Poster Board Number A248) (abstract).
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Cholesterol regulatory genes predict liver transplant outcomes
Researchers identify a link between cholesterol-regulating genes and liver transplant success, which could improve donor screening and patient outcomes.

Lipid signatures for a rare neurological disorder
Researchers find distinct lipid patterns linked to a rare autoimmune neurological disorder, offering hope for effective targeted therapies for patients.

Disease-linked mutations disrupt protein phase behavior
Researchers find that pathogenic missense mutations are enriched threefold in phrase-separating intrinsically disordered regions of proteins.

The dual role of asprosin in chronic fatty liver disease
Researchers uncover a hormone called asprosin that may serve as a potential biomarker for the diagnosis of chronic fatty liver disease and monitoring disease progression.

Novel inhibitor targets RAS-driven cancers
Researchers in Louisville identify a small-molecule drug that blocks RALGEF signaling downstream of mutant RAS. The compound suppresses tumor growth with low toxicity, revealing a new therapeutic strategy for RAS-driven malignancies.

Catching tau in the act
Using a new proximity-labeling approach, researchers reveal how tangles of the brain-associated protein tau may disrupt RNA biology long before neurons die.